LGK974 Potentiates the Lethality of TRAIL in Hepatocellular Carcinoma Cells by Inducing Apoptosis via Suppressing NF-κB Signaling Pathway

LGK974 is a potent Wingless-related integration site inhibitor at Phase II of clinical trial. However, little known about its role and the underlying mechanisms in human hepatocellular carcinoma. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide colony formation assays were used to determine cytotoxicity on liver cancer cell lines. Flow cytometry assay was performed examine apoptosis induced by alone or combination with tumor necrosis factor- related apoptosis-inducing ligand. Western blot evaluate protein expression profiling caspases, poly adenosine diphosphate-ribose polymerase B-cell lymphoma 2 family, as well activation signaling pathways. At present study, we demonstrated that can suppress carcinoma proliferation inducing formation. In addition, effectively inhibited 2, while elevated homologous antagonist/killer, associated agonist death like 11 cells. More interestingly, it observed obviously enhances factor-related ligand apoptosis. Our data indicated not only site/beta catenin pathway, but also inactivated nuclear factor kappa light chain enhancer activated B cells pathway. We pathway using small interfering RNA against polypeptide gene B-cells alpha, which attenuated sensitization effects line, HepG2 Altogether, these presented this study illustrated potentiated lethality via suppressing